PATENT CLAIM ANALYSIS

Application Number: 15750013
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "085100"]

Abstract:
The disclosure provides a new source of peripheral blood naive/memory stem cells (i.e. (T N )/T SCM /T CM ) T-cells with enhanced reconstitution potential and/or longer life spans. It discloses that this particular subset of T-cells can be mobilized by administration of at least one mobilizer in combination with at least one E-Seiectin inhibitor.

Claim (Index 28):
The composition of  claim 27 , further comprising at least one antibody chosen from antibodies against CD44, CD62L, CD45RO, CCR7, CD45RA, CD62L, CD27, CD28, IL-7R\u03b1, CD95, IL-2R\u03b2, CXCR3, and LFA-1.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 88.0
- Lexical Diversity: 1.2449
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14303385', '14006641', '14425713', '12747324', '15316792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7033195280578349
- 35 USC 102 Novelty (BERT): 0.5541935345036536
- Combined Prediction Score: 0.6884069287024168
- Mean Citation Score: 227.991818
- Max Citation Score: 241.22922000000003
- Similarity Product: 158.86455684534076

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test